SBIR/STTR Research Award

Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related Tendinopathy

Award identifier 8151b95075a4b6095b15cf51efcff218e1c87a8be06dd9f561734b53ca3df7d1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$221,826

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Zen-Bio, Inc.
Proposal award date
2018-03-15
Contract end date
2019-02-28
UEI
LQS2WJFBBUQ3
Solicitation number
PAR16-375
Topic code
NIA

Research abstract

Project Summary Chronic tendon injury and tendinopathy are extremely common and painful degenerative conditions whose prevalence reachesin adults overMost of these people don t seek surgical treatmenthowever they do receive injections or physical therapy to improve pain management and regain a small amount of strengthThere are no non surgical tendinopathy therapies that are proven clinically effectivetherefore there is an urgent clinical need for the development of novel therapies for this conditionAdult stem cells are characterized by their self renewing capacity and multipotency making them attractive starting materials for tendonand ligament tissue engineering and regenerative medicine applicationsHowever stem cells do not necessarily repair tissue by differentiating into the desired tissue typebut act more in a regulatory roleThis is accomplished through paracrine effects and cell cell interactions which can be carried out via secreted extracellular vesiclesincluding exosomesIf many of the regenerative properties of stem cells can be credited to exosomesthere will be a paradigm shift in how we view regenerative medicine and therapeutics for many indicationslive cell therapies could be replaced with exosome based biologicsOur focus is to determine the feasibility of using stem cell derived exosomes that have been specifically tuned to break the ineffective repair cycle inherent in tendinopathyProteomic and genomic analysis of exosome content has revealed a broad range of signaling factors that are both cell type specific as well as differentially regulated by the secreting cellsenvironmentBased on these phenomenathis Phase I program is intended to address two hypothesesthe cargo of stem cell derived exosomes can betunedtoward pro healing factors by altering the cellsenvironment andthese pro healing exosomes can be used as a potential tendon healing regenerative therapeuticWe have developed a bioreactor based production system for manufacturing exosomes from various cell typesincluding stem cellsThe bioreactor is an ideal system to test exosome cargo tunabilityproviding a defined environment and optimized exosome purification capabilitiesThis Phaseproject is designed to provide in vitro and in vivo evidence for the further development of this therapeutic approachWe will assess the healing potential of stem cell exosomes derived from two unique tissue sources using our established tenocyte culture systemThis information will provide the basis to test the most effective exosomes in a rat tendon healing modelSuccessful results will lead to further developmentmechanistic studiesagerelated effects and in vivo efficacy assessments in other tendon healing models leading to our ultimate goal of developing an allogeneic therapy for chronic tendinopathy and acute tendon healing Project Narrative Chronic tendon injury and tendinopathy are very common and painful degenerative conditions predominantly afflicting those over the age ofBecause there are no clinically effective nonsurgical treatmentswe plan to exploit stem cell derived extracellular vesicles as a biologic derived therapyleveraging the regenerative and healing properties of adult stem cells to address this unmet clinical need

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

25 SBIR/STTR records share this UEI (2003–2019). Reported award amounts total $16,356,237. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.